Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16738995 | 0.89 | BRD4 (0.48) | BRD4CYP19A1CFDNPC1HTT | |
| SCHEMBL16739026 | 0.89 | BRD4 (0.44) | BRD4CYP19A1CFDHTR6 | |
| SCHEMBL16738991 | 0.88 | BRD4 (0.50) | BRD4CYP19A1CFDNPC1HTT | |
| SCHEMBL16738925 | 0.87 | BRD4 (0.47) | BRD4PKMHTR6 | |
| SCHEMBL16738983 | 0.84 | BRD4 (0.42) | BRD4CYP19A1 | |
| SCHEMBL16738963 | 0.81 | BRD4 (0.49) | BRD4 | |
| SCHEMBL16738911 | 0.76 | BRD4 (0.49) | BRD4MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL16739052 | 0.75 | BRD4 (0.43) | BRD4 | |
| SCHEMBL18382989 | 0.73 | BRD4 (0.39) | BRD4CYP19A1 | |
| SCHEMBL16739011 | 0.73 | BRD4 (0.43) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9918990-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-9918990-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| WO-2015081203-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 4/4885CYP19A1 3799/4885MEN1 2146/4885 |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 4/4885CYP19A1 3799/4885MEN1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.